Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROCLIPI international Study.
暂无分享,去创建一个
U. Wehkamp | R. Cowan | O. Akilov | J. Scarisbrick | L. Cerroni | R. Willemze | E. Guenova | E. Berti | S. Whittaker | P. Ortiz-Romero | C. Querfeld | H. Prince | G. Dunnill | V. Nikolaou | R. Knobler | P. Quaglino | M. Bagot | R. Stadler | R. Matin | E. Papadavid | F. Evison | M. Wobser | M. Marschalkó | L. Geskin | I. Amitay-Laish | E. Hodak | T. Estrach | W. Kempf | O. Servitje | J. Sanches | M. Bayne | S. Weatherhead | M. Vermeer | C. Jonak | C. Mitteldorf | R. Stranzenbach | S. Sherman | A. Bates | E. Hong | S. Alberti-Violetti | J. Yoo | A. Patsatsi | L. Vakeva | Y. Kim | Y. Leshem | M. Beylot‐Barry | H. Prague‐Naveh | A. Buschots
[1] D. Buckley,et al. British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018 , 2018, The British journal of dermatology.
[2] M. Weichenthal,et al. The PROCLIPI international registry of early‐stage mycosis fungoides identifies substantial diagnostic delay in most patients , 2018, The British journal of dermatology.
[3] J. Scarisbrick,et al. Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force. , 2018, European journal of cancer.
[4] J. Scarisbrick,et al. Computed tomography scanning in mycosis fungoides: optimizing the balance between benefit and harm , 2018, The British journal of dermatology.
[5] R. Willemze,et al. Clinical Staging and Prognostic Factors in Folliculotropic Mycosis Fungoides. , 2016, JAMA dermatology.
[6] M. Feinmesser,et al. New insights into folliculotropic mycosis fungoides (FMF): A single-center experience. , 2016, Journal of the American Academy of Dermatology.
[7] J. Cayuela,et al. Lymph node image‐guided core‐needle biopsy for cutaneous T‐cell lymphoma staging , 2016, The British journal of dermatology.
[8] R. Cowan,et al. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] P. Zinzani,et al. Time course, clinical pathways, and long‐term hazards risk trends of disease progression in patients with classic mycosis fungoides , 2012, Cancer.
[10] Wei Wei,et al. Long-term Outcomes of 1,263 Patients with Mycosis Fungoides and Sézary Syndrome from 1982 to 2009 , 2012, Clinical Cancer Research.
[11] J. Scarisbrick,et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Nicola Pimpinelli,et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). , 2007, Blood.
[13] A. Varghese,et al. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. , 2003, Archives of dermatology.
[14] B. Löwenberg,et al. Ultrasound examination of pathological cervical lymph nodes in patients with non‐Hodgkin's lymphoma and Hodgkin's disease , 1994, British journal of haematology.
[15] C. Balu-Maestro,et al. Lymphomatous superficial lymph nodes: US detection. , 1987, Radiology.